The financing will also support Investigational New Drug (IND) filings for several early proprietary development candidates, including its highly selective Amylin peptide agonist (ALV-200)
With the global obesity market projected to reach approximately $150 billion by 20301 and an estimated 4 billion people affected by 20352, this investment reflects Jeito's commitment to addressing one of the world's most pressing health challenges through innovative treatments that offer meaningful benefits to patients
Paris, February 24, 2026, Jeito Capital ("Jeito"), a leading global independent private equity fund dedicated to biopharma, announced today that it was the cornerstone investor in the second closing of the oversubscribed Series A financing of Alveus Therapeutics ("Alveus"), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. This closing brings the total amount raised in the Series A round to $1973 million.Jeito made a significant commitment in the second closing of Series A and was joined by Novo Holdings and other healthcare-focused funds, alongside the original Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi, Kurma Partners, Avego BioScience Capital, and other life sciences investors.
Founded in 2024 and headquartered in Philadelphia, with R&D operations in Copenhagen, Alveus is building a differentiated pipeline of next-generation obesity and metabolic disease therapies designed to deliver sustainable weight loss with superior tolerability and reduced treatment burden, addressing the critical challenge of weight adherence, a key limitation of current treatments. The company is led by an experienced management team with deep expertise in obesity: Raj Kannan, MBA, CEO of Alveus Therapeutics, has led multiple successful licensing transactions and strategic acquisitions at prior biotech companies, including Chiasma and Aerie Pharmaceuticals. ...
